Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2 -Positive Breast Cancer
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.29772 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2024. Verfasst von Heikki Joensuu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The standard adjuvant treatment for patients with ERRB2 -positive breast cancer is chemotherapy plus 1 year of trastuzumab. Shorter durations of trastuzumab administration improve cardiac safety, but more information is needed about their effect on survival.
Objective
To compare survival outcomes after 9-week vs 1-year administration of trastuzumab with the same adjuvant chemotherapy. Design, Setting, and Participants This post hoc secondary analysis of an open-label, multicenter, noninferiority-design randomized clinical trial included women aged 18 years or older with early ERBB2 -positive, axillary node–negative or axillary node–positive breast cancer who were enrolled from January 3, 2008, to December 16, 2014, at 65 centers in 7 European countries. The current exploratory analysis was conducted after achieving the maximum attainable follow-up data when the last patient enrolled had completed the last scheduled visit in December 2022.
Intervention
Chemotherapy consisted of 3 cycles of docetaxel administered at 3-week intervals followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide at 3-week intervals. Trastuzumab was administered in both groups for 9 weeks concomitantly with docetaxel. In the 9-week group, no further trastuzumab was administered after chemotherapy, whereas in the 1-year group, trastuzumab was continued after chemotherapy to complete 1 year of administration. Main Outcomes and Measures The primary objective was disease-free survival (DFS). Distant DFS and OS were secondary objectives. Survival between groups was compared using the Kaplan-Meier method and log-rank test or univariable Cox proportional hazards regression.
Results
Among the 2174 women analyzed, median age was 56 years (IQR, 48-64 years). The median follow-up time was 8.1 years (IQR, 8.0-8.9 years); 357 DFS events and 176 deaths occurred. Trastuzumab for 9 weeks was associated with shorter DFS compared with trastuzumab for 1 year (hazard ratio [HR], 1.36; 90% CI, 1.14-1.62); 10-year DFS was 80.3% in the 1-year group vs 78.6% in the 9-week group. The 5-year and 10-year OS rates were comparable between the 9-week and 1-year groups (95.0% vs 95.9% and 89.1% vs 88.2%, respectively; HR for all time points, 1.20; 90% CI, 0.94-1.54). In multivariable analyses, 9-week treatment was associated with shorter DFS compared with 1-year treatment (HR for recurrence or death, 1.36; 95% CI, 1.10-1.68; P = .005), but there was no between-group difference in OS (HR, 1.22; 95% CI, 0.90-1.64; P = .20). Only 4 patients (0.2%) died of a cardiac cause. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, 1-year vs 9-week adjuvant trastuzumab was associated with improved DFS among patients with ERRB2 -positive breast cancer receiving chemotherapy, but there was no significant difference in OS between the groups. Trial Registration ClinicalTrials.gov Identifier: NCT00593697
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
- Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium.
- Turku University Hospital, Turku, Finland.
- Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
- Örebro University Hospital, Örebro, Sweden.
Zitieren
APA
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., Villman, K. K., Halonen, P., Granstam-Björneklett, H., Tanner, M., Sailas, L., Turpeenniemi-Hujanen, T., Yachnin, J., Huttunen, T., Neven, P., Canney, P., Harvey, V. J., Kellokumpu-Lehtinen, P. L., & Lindman, H. (2024). Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2 -Positive Breast Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.29772
Vancouver
Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2 -Positive Breast Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.29772
BibTeX
@article{Joensuu2024,
author = {Joensuu, Heikki and Fraser, Judith and Wildiers, Hans and Huovinen, Riikka and Auvinen, Päivi and Utriainen, Meri and Villman, Kenneth K and Halonen, Päivi and Granstam-Björneklett, Helena and Tanner, Minna and Sailas, Liisa and Turpeenniemi-Hujanen, Taina and Yachnin, Jeffrey and Huttunen, Teppo and Neven, Patrick and Canney, Peter and Harvey, Vernon J and Kellokumpu-Lehtinen, Pirkko-Liisa and Lindman, Henrik},
title = {Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2 -Positive Breast Cancer},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.29772}
}
EUVIMED